258 related articles for article (PubMed ID: 32677247)
1. A case paradoxical hidradenitis suppurativa with janus kinase inhibitor, literature review and pooled analysis of biological agent-induced HS.
Shaharir SS; Jamil A; Chua SH; Arumugam M; Rosli N
Dermatol Ther; 2020 Nov; 33(6):e14021. PubMed ID: 32677247
[TBL] [Abstract][Full Text] [Related]
2. Observational case series on adalimumab-induced paradoxical hidradenitis suppurativa.
Delobeau M; Abdou A; Puzenat E; Deveza E; Biver-Dalle C; van de Laak A; Roche-Kubler B; Vuitton L; Koch S; Wendling D; Aubin F
J Dermatolog Treat; 2016; 27(3):251-3. PubMed ID: 26368546
[TBL] [Abstract][Full Text] [Related]
3. Hidradenitis suppurativa (HS): An unrecognized paradoxical effect of biologic agents (BA) used in chronic inflammatory diseases.
Faivre C; Villani AP; Aubin F; Lipsker D; Bottaro M; Cohen JD; Durupt F; Jeudy G; Sbidian E; Toussirot E; Badot V; Barbarot S; Debarbieux S; Delaporte E; Goegebeur G; Morel J; Nassif A; Duru G; Jullien D;
J Am Acad Dermatol; 2016 Jun; 74(6):1153-9. PubMed ID: 26965410
[TBL] [Abstract][Full Text] [Related]
4. Paradoxical Hidradenitis Suppurativa in Patients Receiving TNF-α Inhibitors: Case Series, Systematic Review, and Case Meta-Analysis.
Salvador-Rodriguez L; Montero-Vílchez T; Arias-Santiago S; Molina-Leyva A
Dermatology; 2020; 236(4):307-313. PubMed ID: 32135533
[TBL] [Abstract][Full Text] [Related]
5. Adalimumab-Induced Paradoxical Psoriasis Treated with Biologics Targeting the IL-17/IL-23 Axis in Patients with Hidradenitis Suppurativa.
Tsiogka A; Liakou AI; Agiasofitou E; Gregoriou S; Stratigos A; Rigopoulos D; Kontochristopoulos G
Dermatology; 2023; 239(6):937-941. PubMed ID: 37579735
[TBL] [Abstract][Full Text] [Related]
6. Paradoxical hidradenitis suppurativa in Crohn's disease patients receiving infliximab: a case report and review of literature.
Salvatori S; Marafini I; Monteleone G
Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e1046-e1050. PubMed ID: 33905217
[TBL] [Abstract][Full Text] [Related]
7. A systematic review of Janus kinase inhibitors and spleen tyrosine kinase inhibitors for Hidradenitis suppurativa treatment.
Heidari A; Ghane Y; Heidari N; Sadeghi S; Goodarzi A
Int Immunopharmacol; 2024 Jan; 127():111435. PubMed ID: 38150881
[TBL] [Abstract][Full Text] [Related]
8. Paradoxical hidradenitis suppurativa to biologic agents: a case series and literature review.
Neves JM; Cunha N; Lencastre A; Cabete J
Int J Dermatol; 2019 Nov; 58(11):e226-e228. PubMed ID: 31290151
[No Abstract] [Full Text] [Related]
9. Paradoxical psoriasiform reactions during treatment with adalimumab for hidradenitis suppurativa: Real-life experience and therapeutic response to other biological drugs.
Burzi L; Repetto F; Ribero S; Mastorino L; Quaglino P; Dapavo P
Dermatol Ther; 2022 Dec; 35(12):e15866. PubMed ID: 36175129
[TBL] [Abstract][Full Text] [Related]
10. Guselkumab in the treatment of concomitant hidradenitis suppurativa, psoriasis, and Crohn's disease.
Berman HS; Villa NM; Shi VY; Hsiao JL
J Dermatolog Treat; 2021 Mar; 32(2):261-263. PubMed ID: 31389737
[TBL] [Abstract][Full Text] [Related]
11. New onset of articular inflammatory manifestations in patients with hidradenitis suppurativa under treatment with infliximab.
Acquacalda E; Roux CH; Albert C; Breuil V; Passeron T; Euller-Ziegler L
Joint Bone Spine; 2015 Oct; 82(5):362-4. PubMed ID: 25776450
[TBL] [Abstract][Full Text] [Related]
12. Certolizumab pegol in the treatment of severe hidradenitis suppurativa after adalimumab failure: A real-life experience.
Esme P; Akoglu G; Dalkıran CD; Caliskan E
Dermatol Ther; 2022 Nov; 35(11):e15782. PubMed ID: 35996992
[TBL] [Abstract][Full Text] [Related]
13. Reply to 'Paradoxical hidradenitis suppurativa induced by adalimumab biosimilar successfully treated with guselkumab in a patient with psoriasis. Comment on "Paradoxical hidradenitis suppurativa due to anti-interleukin-1 agents for mevalonate kinase deficiency successfully treated with the addition of ustekinumab"'.
López Sanz P; Guzmán Pérez M; Guerrero Ramírez C; Manso Córdoba S; Alfaro Martínez ME; Azaña Defez JM
Clin Exp Dermatol; 2023 Jul; 48(8):940-941. PubMed ID: 37098182
[No Abstract] [Full Text] [Related]
14. Treatment of hidradenitis suppurativa with biologic medications.
Lee RA; Eisen DB
J Am Acad Dermatol; 2015 Nov; 73(5 Suppl 1):S82-8. PubMed ID: 26470624
[TBL] [Abstract][Full Text] [Related]
15. Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials.
Jemec GBE; Okun MM; Forman SB; Gulliver WPF; Prens EP; Mrowietz U; Armstrong AW; Geng Z; Gu Y; Williams DA; Teixeira HD; Kimball AB
Br J Dermatol; 2019 Nov; 181(5):967-975. PubMed ID: 30916379
[TBL] [Abstract][Full Text] [Related]
16. A case of new-onset vitiligo in a patient on tofacitinib and brief review of paradoxical presentations with other novel targeted therapies.
Nguyen JK; Schlichte MJ; Jogi R; Alikhan M; Patel AB
Dermatol Online J; 2020 Mar; 26(3):. PubMed ID: 32609446
[TBL] [Abstract][Full Text] [Related]
17. Adalimumab Treatment in Women With Moderate-to-Severe Hidradenitis Suppurativa from the Placebo-Controlled Portion of a Phase 2, Randomized, Double-Blind Study.
Gottlieb A; Menter A; Armstrong A; Ocampo C; Gu Y; Teixeira HD
J Drugs Dermatol; 2016 Oct; 15(10):1192-1196. PubMed ID: 27741335
[TBL] [Abstract][Full Text] [Related]
18. Secukinumab-induced paradoxical hidradenitis suppurativa.
Navarro-Triviño FJ; Sanchez-Parera R; Ruiz-Villaverde R
Dermatol Ther; 2020 Jan; 33(1):e13150. PubMed ID: 31670893
[TBL] [Abstract][Full Text] [Related]
19. Safety of Adalimumab Dosed Every Week and Every Other Week: Focus on Patients with Hidradenitis Suppurativa or Psoriasis.
Ryan C; Sobell JM; Leonardi CL; Lynde CW; Karunaratne M; Valdecantos WC; Hendrickson BA
Am J Clin Dermatol; 2018 Jun; 19(3):437-447. PubMed ID: 29380251
[TBL] [Abstract][Full Text] [Related]
20. Paradoxical psoriasis induced by TNF-α blockade shows immunological features typical of the early phase of psoriasis development.
Fania L; Morelli M; Scarponi C; Mercurio L; Scopelliti F; Cattani C; Scaglione GL; Tonanzi T; Pilla MA; Pagnanelli G; Mazzanti C; Girolomoni G; Cavani A; Madonna S; Albanesi C
J Pathol Clin Res; 2020 Jan; 6(1):55-68. PubMed ID: 31577850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]